Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6 Mln
Revenue (TTM)
$3 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
1
Div. Yield
0 %
Debt to Equity
--
Book Value
$3.2
EPS
$-1.2
Face value
--
Shares outstanding
2,291,056
CFO
$-55.55 Mln
EBITDA
$-99.44 Mln
Net Profit
$-134.83 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Xenetic Biosciences (XBIO)
| 38.7 | 19.0 | 38.7 | 22.4 | -9.5 | -32.2 | -45.2 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Xenetic Biosciences (XBIO)
| -45.6 | 15.5 | 21.0 | -77.9 | -36.8 | 41.7 | -92.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Xenetic Biosciences (XBIO)
|
3.0 | 6.1 | 3.0 | -2.7 | -54.4 | -40 | -- | 0.9 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and... progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. Address: 945 Concord Street, Framingham, MA, United States, 01701 Read more
CEO, President & Director
Mr. Jeffrey F. Eisenberg Esq.
CEO, President & Director
Mr. Jeffrey F. Eisenberg Esq.
Headquarters
Framingham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Xenetic Biosciences Inc (XBIO) is $3.01 (NASDAQ) as of 02-Apr-2026 16:32 EDT. Xenetic Biosciences Inc (XBIO) has given a return of -9.49% in the last 3 years.
Since, TTM earnings of Xenetic Biosciences Inc (XBIO) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.85
|
0.67
|
|
2024
|
-1.55
|
1.02
|
|
2023
|
-1.28
|
0.54
|
|
2022
|
-0.07
|
0.03
|
|
2021
|
-0.23
|
0.07
|
The 52-week high and low of Xenetic Biosciences Inc (XBIO) are Rs 13.93 and Rs 1.90 as of 05-Apr-2026.
Xenetic Biosciences Inc (XBIO) has a market capitalisation of $ 6 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Xenetic Biosciences Inc (XBIO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.19
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.